In combination therapy, together with anti-PD-1 antibodies and conventional chemotherapy, these antibodies demonstrate activity in the treatment of NSCLC, small-cell lung cancer (SCLC), squamous cell carcinoma of the esophagus, hematological malignancies, and melanoma [370,390,405]. This evidence concerns the gene PDCD1 and melanoma.